1. Pink Sheet
  2. >>Drug Safety

Mifepristone REMS For Pharmacies Contains Some Unusual Provisions, Continues Debate Over Access

 
• By Brenda Sandburg

After FDA clears modified REMS, certified retail pharmacists are permitted to dispense the abortion medication. Some advocates argue program is unnecessary, while others want a broader federal effort to expand access. Walgreens intends to become a certified pharmacy.

Pharmacy
Abortion drug mifepristone to be available in certified pharmacies • Source: Shutterstock

The US Food and Drug Administration approved modifications to the Risk Evaluation and Mitigation Strategy for mifepristone that permit retail pharmacists, as well as online pharmacists, to be certified to dispense the medication abortion. The change is expected to expand access, but many contend that a uniform federal program is needed to help those in states that ban or restrict use of the medication.

The US Food and Drug Administration announced in December 2021 that the REMS would be modified to remove the requirement...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Safety

More from Pink Sheet

Recent And Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK-Wide Strategy Needed To Move Clinical Trial Diversity Plans To Next Stage

 
• By Vibha Sharma

The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.

Blenrep’s Comeback Continues As England Becomes First To Fund Drug

 
• By Eliza Slawther

Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.